🏛️ Verified NIH Record • Updated 2026-08-17
Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission (NCT02140255)
Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission: A Phase I/II Proof of Concept Study
🟢 Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
🩺 Plain-English Summary (8th-Grade Level)
The study will explore the effects of early intensive antiretroviral therapy (ART) with or without a broadly neutralizing antibody (bNAb) on achieving HIV remission (HIV RNA below the limit of detection of the assay) among infants living with HIV.
Who can join: Review the eligibility criteria below.
Location: 4601, University of California, San Diego Clinical Research Site — La Jolla, California
Age range: Not specified to 48 Hours
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (46 Sites)
Showing the first 25 of 46 sites.
- 4601, University of California, San Diego Clinical Research Site — La Jolla, California
- 5048, University of Southern California Clinical Research Site — Los Angeles, California
- 5112, David Geffen School of Medicine at UCLA Clinical Research Site — Los Angeles, California
- 5052, University of Colorado, Denver Clinical Research Site — Aurora, Colorado
- 5055, South Florida CDTC Fort Lauderdale Clinical Research Site — Fort Lauderdale, Florida
- 5051, University of Florida Center for HIV/AIDS Research, Education and Service (UF CARES) Clinical Research Site — Jacksonville, Florida
- 5127, Pediatric Perinatal HIV Clinical Research Site — Miami, Florida
- Emory University School of Medicine NICHD CRS — Atlanta, Georgia
- 5083, Rush University Cook County Hospital Clinical Research Site — Chicago, Illinois
- 4001, Lurie Children's Hospital of Chicago Clinical Research Site — Chicago, Illinois
- 5092, Johns Hopkins Clinical Research Site — Baltimore, Maryland
- Boston Medical Center Ped. HIV Program NICHD CRS — Boston, Massachusetts
- 5040, SUNY Stony Brook Clinical Research Site — Stony Brook, New York
- 5114, Bronx Lebanon Hospital Center Clinical Research Site — The Bronx, New York
- 5013, Jacobi Medical Center Clinical Research Site — The Bronx, New York
- Philadelphia IMPAACT Unit CRS — Philadelphia, Pennsylvania
- 6501, St Jude Children's Research Hospital Clinical Research Site — Memphis, Tennessee
- 5128, Baylor College of Medicine/Texas Children's Hospital Clinical Research Site — Houston, Texas
- Seattle Children's Research Institute CRS — Seattle, Washington
- Univ. of Washington NICHD CRS — Seattle, Washington
- Hosp. General de Agudos Buenos Aires Argentina NICHD CRS — Buenos Aires,
- Hospital Nossa Senhora da Conceicao NICHD CRS — Porto Alegre, Rio Greande Do Sul
- 5073, School of Medicine Federal University Minas Gerais Clinical Research Site — Minas Gerais,
- 5072, Hospital Federal dos Servidores do Estado Clinical Research Site — Rio de Janeiro,
- 5071, Instituto de Puericultura e Pediatria Martagao Gesteira Clinical Research Site — Rio de Janeiro,
📞 Contact the Study Coordinator
Phone: (919) 627-6445
Email: acoletti@fhi360.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in HIV Infection
- Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant — La Jolla, California
- Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption — Birmingham, Alabama
- A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054) — Birmingham, Alabama
- Baricitinib Curative Repression of HIV-1 — Atlanta, Georgia
- Duo: A Phase IIIb Individual-Level Randomized Controlled Trial of an Integrated Strategy — Los Angeles, California
- Impact of Behavior Modification Interventions and Lung Cancer Screening on Smoking Cessation in People Living With HIV: A Feasibility Study — La Jolla, California
Explore by condition: All HIV Infection clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.